NCT03095248
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors treatment 2 completed NCT00004483
NF2 Natural History Consortium No drug interventions Not Available Not Available unknown_status NCT00004437
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 No drug interventions treatment 2 completed NCT02298270
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype No drug interventions supportive_care Not Available completed NCT03079999
Study of Aspirin in Patients With Vestibular Schwannoma treatment 2 recruiting NCT05685836
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients Not Available Not Available recruiting NCT00973739
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors treatment 2 completed NCT01490476
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients treatment 2 completed NCT04283669
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas other 2 active_not_recruiting NCT03406208
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing No drug interventions treatment Not Available unknown_status NCT00030043
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors No drug interventions treatment 1 completed NCT03893643
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 No drug interventions Not Available Not Available unknown_status NCT04890132
Vestibular Precision: Physiology & Pathophysiology No drug interventions basic_science Not Available enrolling_by_invitation NCT02811718
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype No drug interventions treatment Not Available completed NCT00863122
Concentration and Activity of Lapatinib in Vestibular Schwannomas basic_science 0 completed NCT00911248
PTC299 for Treatment of Neurofibromatosis Type 2 treatment 2 terminated NCT02831257
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas treatment 2 completed NCT03617276
Reliability of Functional Outcome Measures in Neurofibromatosis 2 No drug interventions Not Available Not Available completed NCT01885767
Neurofibromatosis (NF) Registry Portal No drug interventions Not Available Not Available recruiting NCT01207687
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) treatment 2 completed NCT02129647
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas treatment 2 completed NCT04374305
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) treatment 2 recruiting NCT03210285
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data No drug interventions Not Available Not Available completed NCT01345136
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma treatment 2 terminated NCT05130866
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas treatment 2 / 3 recruiting NCT01767792
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas treatment 2 completed NCT02589912
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients No drug interventions Not Available Not Available no_longer_available NCT02934256
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors treatment 2 completed NCT01880749
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas other 0 completed NCT02282917
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma treatment 0 terminated NCT01552434
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease treatment 1 active_not_recruiting NCT05521048
Doxycycline in Cutaneous Schwannoma (NF2) treatment 1 / 2 recruiting NCT02246231
Effect of Implant Position on Magnetic Resonance Image Distortion No drug interventions diagnostic Not Available completed NCT01125046
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas treatment 2 completed NCT02104323
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors treatment 2 completed NCT01419639
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 treatment 2 completed NCT03050268
Familial Investigations of Childhood Cancer Predisposition No drug interventions Not Available Not Available recruiting